.Pharmacolibrary.Drugs.A_AlimentaryTractAndMetabolism.A06A_DrugsForConstipation.A06AH01_MethylnaltrexoneBromide.MethylnaltrexoneBromide .Pharmacolibrary.Drugs.A_AlimentaryTractAndMetabolism.A06A_DrugsForConstipation.A06AH01_MethylnaltrexoneBromide.MethylnaltrexoneBromide| name: | MethylnaltrexoneBromide |
| ATC code: | A06AH01 | route: | subcutaneous |
| n-compartments | 2 |
Methylnaltrexone bromide is a peripherally-acting μ-opioid receptor antagonist (PAMORA) used to treat opioid-induced constipation in adult patients with chronic non-cancer pain or advanced illness. It is approved for clinical use and marketed under several names, including Relistor.
Pharmacokinetic parameters reported in healthy adult subjects after a single subcutaneous injection.
Rotshteyn, Y, et al., & Yuan, CS (2011). Methylnaltrexone bromide: research update of pharmacokinetics following parenteral administration. Expert opinion on drug metabolism & toxicology 7(2) 227–235. DOI:10.1517/17425255.2011.549824 PUBMED:https://pubmed.ncbi.nlm.nih.gov/21222554
Mozaffari, S, et al., & Abdollahi, M (2018). Methylnaltrexone bromide for the treatment of opioid-induced constipation. Expert opinion on pharmacotherapy 19(10) 1127–1135. DOI:10.1080/14656566.2018.1491549 PUBMED:https://pubmed.ncbi.nlm.nih.gov/29979903
Zhang, D, et al., & Liu, H (2018). Pharmacokinetic study of methylnaltrexone after single and multiple subcutaneous administrations in healthy Chinese subjects. Xenobiotica; the fate of foreign compounds in biological systems 48(8) 804–808. DOI:10.1080/00498254.2017.1364449 PUBMED:https://pubmed.ncbi.nlm.nih.gov/28776489